Novartis AG
Antibody molecules to PD-L1 and methods of treating cancer
Last updated:
Abstract:
Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
Status:
Grant
Type:
Utility
Filling date:
20 Feb 2018
Issue date:
1 Dec 2020